Repatha Field Team downsizing after Sanofi cuts first

Sanofi will be downsizing their field team for Praluent in the next couples of weeks after earnings are announced. Amgen will be a fast follower and do the same as well citing competitive pressures to lower cost as both products have disappointed. By following Sanofi's lead, management can tell the remaining reps that it was forced to do so on a competitive cost-basis. This puts Sanofi as the bad guy and allows Amgen CV management the excuse to resize and reorganize the Repatha team without being perceived as the bad guy. The results will be less reps and many converted to inVentiv for added flexibility. Both companies expect a CV benefit, however, the benefit is not sufficient to justify the price, access and large scale population they were targeting making both drugs like mid 1990's primary care statins.

 

Looks to be true as the Sanofi PC Praluent team is freaking out.

http://cafepharma.com/boards/threads/praluent-pc-team-and-diabetes-pc-team-judgement-day-is-coming.601048/

 

Many would embrace a downsizing.....However, i think we are in for one more year of pain before rational thought wins the day...... We should have two sales forces, one bone, one CV, reps call on all targets in their territory....Why in the world are we creating a ROMO sales force with a huge geography who will make 2 calls a day?......This place is out of hand.

 

Why does romo needs its own sales force? Isn't it mostly rheums that enbrel reps call on?

 

Exactly- Enbrel reps "call" on Rheums- Gen Med reps actually sell